Last reviewed · How we verify
NCT06125535: LUTX_phenotype
Biomolecular Phenotyping of Lung Transplant Recipients
trial testing Sub-phenotyping by biomarkers concentration in Lung Transplant Failure in 80 participants. Completed in 1 June 2025.
1 March 2024
Quick facts
| Lead sponsor | Policlinico Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 80 |
| Start date | 1 February 2022 |
| Primary completion | 1 March 2024 |
| Estimated completion | 1 June 2025 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Sub-phenotyping by biomarkers concentration
Conditions studied
- Lung Transplant Failure — all drugs for Lung Transplant Failure →
Sponsor
Policlinico Hospital
Who can join
18 and older, any sex, with Lung Transplant Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Primary graft dysfunction (PGD) is a common problem after a lung transplant. It's a sudden lung injury that affects around 30% of patients within 72 hours of getting a new lung. PGD can vary in severity, from mild issues seen on X-rays to severe lung problems, and it can also affect other parts of the body, like the heart and kidneys. The investigators believe that using precision medicine can identify different groups of patients with varying levels of inflammation and provide them with treatments tailored to their specific conditions. This approach has been successful in treating other serious conditions like acute respiratory distress syndrome (ARDS). Currently, researchers haven't classified lung transplant patients in this way, and there's limited information on early blood markers for PGD. In an upcoming study, the investigators aim to group lung transplant patients based on their blood markers related to inflammation, blood clotting, and blood vessel problems. The investigators also want to see if these groups are linked to their overall outcomes, especially when it comes to PGD.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06125535
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Transplant Failure
Currently open trials in the same condition.
- NCT06399302 — Prospective Multicenter Research on Donor and Recipient Management Strategies to Improve Lung Transplant Outcomes · recruiting
- NCT05526950 — Cytokine Filtration in Lung Transplantation: A Swedish National Study (GLUSorb) · NA · recruiting
Other Policlinico Hospital trials
Trials by the same sponsor.
- NCT06848010 — TRacheal Cuff PRessure Evaluation Study · NA · not yet recruiting
- NCT06583642 — Antimicrobial Therapeutic Drug Monitoring During Lung Transplant Perioperative Phase · not yet recruiting
- NCT06302192 — Renal Doppler to Predict Acute Kidney Injury (AKI) in ARDS Patients. (RED-AKI Study) · not yet recruiting
- NCT06312488 — Point of Care Evaluation of Fibrinolysis in Sepsis · NA · completed
- NCT06395259 — Observational Study on the Variation of Ascorbic Acid in Patients Undergoing Solid Organ Transplantation · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06125535 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Policlinico Hospital
- Last refreshed: 18 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06125535.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing